Crestor vs Amlodipine: Switching Between Them

Why These Two Drugs Are Not Interchangeable

Rosuvastatin and amlodipine act on entirely separate pathways. Confusing one for the other, or dropping one to start the other, leaves a distinct cardiovascular risk factor unchecked.

Rosuvastatin (brand name Crestor) inhibits HMG-CoA reductase, the rate-limiting enzyme in hepatic cholesterol synthesis. By blocking this enzyme, it upregulates LDL receptor expression on hepatocytes, pulling LDL particles out of circulation. At 10 to 40 mg daily, rosuvastatin lowers LDL-C by 46% to 55%, making it the most potent statin per milligram on the market [1]. The JUPITER trial (N=17,802) demonstrated that rosuvastatin 20 mg reduced the composite endpoint of myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or confirmed cardiovascular death by 44% (HR 0.56; 95% CI, 0.46 to 0.69; P<0.00001) in apparently healthy individuals with LDL-C <130 mg/dL but hsCRP ≥2.0 mg/L [1].

Amlodipine belongs to the dihydropyridine calcium channel blocker (CCB) class. It relaxes vascular smooth muscle by blocking L-type calcium channels, reducing peripheral vascular resistance and systolic blood pressure by roughly 10 to 15 mmHg at 5 to 10 mg daily [2]. In the ASCOT-BPLA trial (N=19,257), an amlodipine-based regimen (with perindopril added as needed) produced fewer cardiovascular events, fewer strokes, and lower all-cause mortality than an atenolol-based comparator over a median 5.5 years of follow-up [2].

The 2017 ACC/AHA Hypertension Guideline lists CCBs including amlodipine as a first-line option for stage 1 hypertension, while the 2018 ACC/AHA Cholesterol Guideline positions high-intensity statins (rosuvastatin 20 to 40 mg) as first-line therapy for ASCVD risk reduction [3][4]. These are parallel, not competing, recommendations.

When a Clinician Might Adjust Both Drugs

A patient may present with both elevated LDL and elevated blood pressure. The question is rarely "which one do I choose?" but rather "do I need to adjust one or both?"

Scenario one: a patient on rosuvastatin 10 mg with well-controlled LDL (say, 68 mg/dL) is found to have a systolic blood pressure of 142 mmHg at two consecutive visits. Adding amlodipine 5 mg addresses the new finding without removing the statin. The ACC/AHA recommends treating to a BP target of <130/80 mmHg in most adults with increased cardiovascular risk [3].

Scenario two: a patient on amlodipine 10 mg with controlled blood pressure receives new lab results showing LDL-C of 162 mg/dL and a 10-year ASCVD risk of 12%. Current guidelines call for moderate- to high-intensity statin therapy when 10-year risk exceeds 7.5% [4]. Adding rosuvastatin 10 to 20 mg is the standard move.

Scenario three (the true "switch" case): a patient who was started on amlodipine for suspected hypertension turns out to have white-coat hypertension confirmed by ambulatory monitoring, but their lipid panel reveals an LDL-C of 190 mg/dL. Here, the clinician may discontinue amlodipine and start rosuvastatin instead, because the original indication (hypertension) was incorrect and a new one (severe hypercholesterolemia) now exists. This is not really "switching between" two treatments for the same condition. It is correcting a diagnosis.

The 2019 ESC/EAS Dyslipidemia Guidelines state: "In patients at very high cardiovascular risk, an LDL-C reduction of ≥50% from baseline and an LDL-C goal of <1.4 mmol/L (<55 mg/dL) are recommended" [5]. Amlodipine cannot achieve this. Only lipid-lowering therapy can.

The ASCOT Evidence for Combining a Statin With Amlodipine

The strongest evidence for using both drug classes together comes from the lipid-lowering arm of ASCOT, known as ASCOT-LLA.

ASCOT-LLA (N=10,305) randomized hypertensive patients with at least three additional cardiovascular risk factors and total cholesterol ≤6.5 mmol/L to atorvastatin 10 mg or placebo on top of their blood pressure regimen [6]. The trial was stopped early at a median of 3.3 years because atorvastatin reduced the primary endpoint (non-fatal MI and fatal coronary heart disease) by 36% (HR 0.64; 95% CI, 0.50 to 0.83; P=0.0005) [6].

A pre-specified subgroup analysis found that the benefit was concentrated in patients randomized to the amlodipine-based BP arm rather than the atenolol-based arm. In the amlodipine subgroup, atorvastatin cut coronary events by 53% [7]. The authors of a subsequent analysis published in the European Heart Journal noted: "The interaction between the amlodipine-based regimen and atorvastatin suggests synergistic cardiovascular protection beyond what either agent achieves alone" [7].

While ASCOT-LLA used atorvastatin rather than rosuvastatin, both are high-potency statins. A meta-analysis of 26 randomized trials (N=170,000) by the Cholesterol Treatment Trialists' Collaboration found that each 1.0 mmol/L (39 mg/dL) reduction in LDL-C from any statin reduces major vascular events by approximately 22% [8]. The protective effect is proportional to LDL-C lowering, regardless of which statin is used.

Pharmacokinetic Considerations When Taking Both

Rosuvastatin and amlodipine do not share metabolic pathways in a clinically meaningful way, which simplifies co-prescribing.

Rosuvastatin undergoes minimal CYP450 metabolism. Approximately 10% is metabolized by CYP2C9, with the rest excreted largely unchanged via bile and feces [9]. Amlodipine is metabolized primarily by CYP3A4, with a long elimination half-life of 30 to 50 hours [10]. Because rosuvastatin does not depend on CYP3A4, the drug-drug interaction risk between these two agents is negligible.

This is a relevant distinction compared to some other statin-CCB combinations. Simvastatin and lovastatin, for example, are extensively metabolized by CYP3A4. Co-administration with amlodipine or diltiazem can raise simvastatin plasma levels, increasing myopathy risk. The FDA limits simvastatin to 20 mg daily when combined with amlodipine [11]. No such restriction exists for rosuvastatin.

For patients already taking amlodipine who need a statin, rosuvastatin or pravastatin (which also bypasses CYP3A4) may be preferred over simvastatin or lovastatin specifically because of this clean interaction profile [9].

Side Effect Profiles: What to Expect From Each

The adverse-effect patterns of these two drugs are distinct, which matters when attributing symptoms during combination therapy.

Rosuvastatin's most reported side effects include myalgia (affecting roughly 5% to 10% of patients in observational studies), elevated hepatic transaminases (0.2% to 0.4% at high doses), and, rarely, new-onset diabetes. The JUPITER trial found that rosuvastatin increased physician-reported diabetes by a relative 27% (3.0% vs. 2.4% over 1.9 years; P=0.01), primarily in patients with baseline metabolic syndrome or impaired fasting glucose [1]. A subsequent analysis found that the cardiovascular benefit outweighed this diabetogenic risk by a ratio of approximately 2:1 in at-risk individuals [12].

Amlodipine's most common side effect is peripheral edema, occurring in about 10.8% of patients at 10 mg daily compared to 0.6% on placebo in the manufacturer's clinical trial program [10]. Headache, dizziness, and flushing also occur, particularly during the first two weeks. Gingival hyperplasia is a recognized but uncommon effect, reported in roughly 1% to 3% of long-term users [13].

Dr. Paul Ridker, principal investigator of JUPITER, noted in a 2012 review: "Statin-associated muscle symptoms remain the primary reason for discontinuation in clinical practice, yet the nocebo effect accounts for a substantial proportion of reported myalgias" [14]. The SAMSON trial (N=60) later confirmed this observation, finding that 90% of statin side-effect burden was replicated by placebo [15].

If a patient on both drugs reports muscle pain, the clinician should check creatine kinase levels and consider a trial off the statin, because amlodipine is not a known cause of myalgia.

Cost and Access Differences

Both rosuvastatin and amlodipine are available as generics, but price gaps exist.

Generic rosuvastatin 10 mg costs approximately $10 to $25 for a 30-day supply at most U.S. retail pharmacies, according to GoodRx pricing data. Generic amlodipine 5 mg is one of the least expensive prescription drugs in the United States, frequently priced at $4 for a 30-day supply through major pharmacy discount programs [16].

Brand-name Crestor, where still dispensed, can cost $300 or more per month without insurance. The patent for rosuvastatin expired in 2016, so generic availability is widespread.

For patients on both medications, a fixed-dose combination pill (amlodipine/atorvastatin, marketed as Caduet) exists but uses atorvastatin rather than rosuvastatin. No FDA-approved fixed-dose combination of amlodipine with rosuvastatin is currently available in the U.S. market. The 2022 AHA Scientific Statement on polypill strategies acknowledged that single-pill combinations improve adherence by 20% to 30% compared to multi-pill regimens in hypertension and dyslipidemia management [17].

Who Should Not Take One or Both

Contraindications differ between these agents, and knowing them prevents errors during prescribing transitions.

Rosuvastatin is contraindicated in active liver disease (transaminases >3× the upper limit of normal), pregnancy, and breastfeeding. The FDA recommends a starting dose of 5 mg in patients of Asian descent due to higher drug exposure, and a maximum of 20 mg in patients with severe renal impairment (CrCl <30 mL/min) [9].

Amlodipine is contraindicated in severe aortic stenosis and should be used cautiously in patients with decompensated heart failure. While dihydropyridine CCBs were once suspected of worsening heart failure, the PRAISE trial (N=1,153) showed that amlodipine did not increase morbidity or mortality in patients with NYHA class III-IV heart failure and ejection fractions <30% [18].

A patient switching from one drug to the other should have the new indication confirmed. Stopping a statin in a patient with established ASCVD raises LDL-C back to baseline within two to three weeks and eliminates the pleiotropic anti-inflammatory benefits demonstrated in JUPITER [1]. Stopping amlodipine without an alternative antihypertensive can produce rebound blood pressure elevation, though this is less abrupt than with beta-blockers or clonidine.

Clinical Decision Framework: One, the Other, or Both

The decision tree is straightforward when framed by each drug's indication.

If the patient has isolated dyslipidemia with normal blood pressure: rosuvastatin alone, dosed to achieve guideline LDL-C targets. If the patient has isolated hypertension with acceptable lipids and low ASCVD risk: amlodipine alone (or another first-line antihypertensive).

If the patient has both elevated LDL-C and elevated blood pressure, which describes a large share of adults over 50: both drugs together. The ACC/AHA Pooled Cohort Equations estimate 10-year ASCVD risk using both systolic BP and total/HDL cholesterol ratio, meaning both parameters directly feed the treatment algorithm [4].

Dr. Neil Poulter, a lead ASCOT investigator, wrote in the Lancet: "The combination of a calcium channel blocker-based blood pressure regimen with statin therapy offers a greater reduction in cardiovascular morbidity than treating either risk factor in isolation" [2]. The data support this position. ASCOT's factorial design showed that the greatest event reduction occurred in patients randomized to both the amlodipine arm and the atorvastatin arm simultaneously [7].

For the average patient asking whether Crestor is "better than" amlodipine, the answer is that the comparison does not apply. They target different physiologic systems. Asking which is better is like asking whether insulin is better than lisinopril. The correct question is: which risk factors does this patient have, and are both being treated to target?

Patients with an LDL-C above 190 mg/dL require high-intensity statin therapy regardless of other medications [4]. Patients with stage 2 hypertension (≥140/90 mmHg) require antihypertensive therapy regardless of lipid status [3]. Many patients need both.